Cargando…
Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases
Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081430/ https://www.ncbi.nlm.nih.gov/pubmed/35548357 http://dx.doi.org/10.3389/fphar.2022.897539 |
_version_ | 1784702985923723264 |
---|---|
author | Li, Jiadong Yin, Zhifeng Huang, Biaotong Xu, Ke Su, Jiacan |
author_facet | Li, Jiadong Yin, Zhifeng Huang, Biaotong Xu, Ke Su, Jiacan |
author_sort | Li, Jiadong |
collection | PubMed |
description | Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of pathological processes including immune escape, tumorigenesis, and inflammation. In the bone microenvironment, Stat3 acts as a common downstream response protein for multiple cytokines and is engaged in the modulation of cellular proliferation and intercellular interactions. Stat3 has direct impacts on disease progression by regulating mesenchymal stem cells differentiation, osteoclast activation, macrophage polarization, angiogenesis, and cartilage degradation. Here, we describe the theoretical basis and key roles of Stat3 in different bone-related diseases in combination with in vitro experiments and animal models. Then, we summarize and categorize the drugs that target Stat3, providing potential therapeutic strategies for their use in bone-related diseases. In conclusion, Stat3 could be a future target for bone-related diseases. |
format | Online Article Text |
id | pubmed-9081430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90814302022-05-10 Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases Li, Jiadong Yin, Zhifeng Huang, Biaotong Xu, Ke Su, Jiacan Front Pharmacol Pharmacology Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of pathological processes including immune escape, tumorigenesis, and inflammation. In the bone microenvironment, Stat3 acts as a common downstream response protein for multiple cytokines and is engaged in the modulation of cellular proliferation and intercellular interactions. Stat3 has direct impacts on disease progression by regulating mesenchymal stem cells differentiation, osteoclast activation, macrophage polarization, angiogenesis, and cartilage degradation. Here, we describe the theoretical basis and key roles of Stat3 in different bone-related diseases in combination with in vitro experiments and animal models. Then, we summarize and categorize the drugs that target Stat3, providing potential therapeutic strategies for their use in bone-related diseases. In conclusion, Stat3 could be a future target for bone-related diseases. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9081430/ /pubmed/35548357 http://dx.doi.org/10.3389/fphar.2022.897539 Text en Copyright © 2022 Li, Yin, Huang, Xu and Su. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Jiadong Yin, Zhifeng Huang, Biaotong Xu, Ke Su, Jiacan Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases |
title | Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases |
title_full | Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases |
title_fullStr | Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases |
title_full_unstemmed | Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases |
title_short | Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases |
title_sort | stat3 signaling pathway: a future therapeutic target for bone-related diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081430/ https://www.ncbi.nlm.nih.gov/pubmed/35548357 http://dx.doi.org/10.3389/fphar.2022.897539 |
work_keys_str_mv | AT lijiadong stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases AT yinzhifeng stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases AT huangbiaotong stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases AT xuke stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases AT sujiacan stat3signalingpathwayafuturetherapeutictargetforbonerelateddiseases |